Related Experiment Video
Updated: Mar 12, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
1.2K
Phosphorus as predictive factor for erectile dysfunction in middle aged men: A cross sectional study in Korea
Seung Ki Min1, Kwibok Choi1, Soon Ki Kim1
1Department of Urology, National Police Hospital, Seoul, Korea.
Investigative and Clinical Urology
|November 17, 2016
Summary
High serum phosphorus levels are linked to erectile dysfunction (ED) in middle-aged men. Managing phosphorus may help prevent ED, highlighting its role as a modifiable risk factor.
Area of Science:
- Urology
- Endocrinology
- Cardiovascular Science
Background:
- High serum inorganic phosphorus is associated with cardiovascular disease.
- The relationship between phosphorus and erectile dysfunction (ED) is not well-established.
- Understanding novel risk factors for ED is crucial for public health.
Purpose of the Study:
- To investigate the association between serum phosphorus levels and erectile dysfunction (ED).
- To identify clinical variables associated with ED in middle-aged men.
- To determine if phosphorus is an independent predictor of ED.
Main Methods:
- A cross-sectional study of 1,899 men aged 40-59 years undergoing prostate health screening.
- Assessment of erectile function using the International Index of Erectile Function-5 (IIEF-5) questionnaire.
- Analysis of serum inorganic phosphorus, prostate-specific antigen (PSA), testosterone, body mass index (BMI), and metabolic syndrome (MetS).
Main Results:
- Serum inorganic phosphorus showed a significant negative correlation with IIEF-5 scores (r=-0.108, p<0.001).
- Age, metabolic syndrome (MetS), and serum phosphorus were identified as independent predictors of moderate to severe ED in multivariate analysis.
- Prostate-specific antigen (PSA), testosterone, BMI, and prostate volume did not predict ED.
Conclusions:
- Serum phosphorus levels are significantly associated with erectile dysfunction (ED) in middle-aged men.
- Phosphorus is a modifiable risk factor and an independent predictor of ED.
- Controlling serum phosphorus may be a strategy for preventing ED.
Related Concept Videos
01:20Disorders of the Male Reproductive System
5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
307
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
307
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
302
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
302
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
678
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
678
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
307
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
307